Paroxysmal supraventricular tachycardia (PSVT)

News

Paroxysmal supraventricular tachycardia (PSVT) is a type of abnormal heart rhythm (arrhythmia) characterized by unpredictable acute episodes in which the heartbeat commonly exceeds 150-200bpm. Abrupt SVT episodes commonly lead to palpitations, shortness of breath, chest pressure, lightheadedness, fatigue and anxiety. PSVT is caused by abnormal electrical connections in the heart that cause irregular contraction.

Approximately 2.3-4 in 1,000 people have PSVT, resulting in an estimated overall patient population of 3-6 million in China. Current treatments for termination of acute episodes require emergency setting administration of IV calcium channel blockers and IV antiarrhythmics. Patients typically have multiple, unpredictable PSVT episodes per year, leading to a significant impact on their quality of life. An operative procedure, called ablation, is currently the only way to successfully restore normal heart function and mitigate future PSVT episodes.

Etripamil nasal spray is a disruptive calcium channel blocker designed to keep patients out of the emergency room (ER) and operating room (OR). Etripamil can be self-administered, enabling a convenient and effective rapid treatment outside of the hospital setting. Etripamil is positioned to significantly alter the acute treatment of PSVT, allowing patients to quickly terminate episodes without the fear or inconvenience of having to rush to the ER for treatment.

Our partner, Milestone Pharmaceuticals, is currently conducting a second registrational Phase 3 trial in PSVT. In China, JIXING will conduct a Phase 1 study to evaluate the safety and tolerability of etripamil in healthy Chinese subjects and a Phase 3 study to evaluate the efficacy and safety of etripamil nasal spray self-administration in PSVT. Both clinical trials will start in 2022. 

For further information about our partner, Milestone Pharmaceuticals, please visit https://milestonepharma.com/

Scroll to Top